No specific treatment has been identified to date for Chikungunya infection, especially for severe neonatal forms. While efficacy and safety of anti-CHIKV hyperimmune immunoglobulins have been demonstrated in neonate mice, to date no such study has been performed in humans. Therefore this study would be first to assess this promising therapeutic intervention.